东莞市凯法生物医药

Dongguan Kaifa Biopharmaceutical is a biotechnology company specializing in the development of next-generation small molecule therapeutics using Proteolysis Targeting Chimera (PROTAC) technology. Based in Dongguan, China, the company focuses on addressing unmet medical needs in oncology and metabolic disorders by degrading specific disease-related proteins. Their research pipeline includes programs targeting the androgen receptor for prostate cancer and the estrogen receptor for breast cancer. The company aims to overcome drug resistance associated with traditional inhibitors through its innovative protein degradation platform, led by a team of experienced pharmaceutical R&D professionals.